Table 1.

Clinical and pathologic characteristics of the patient population overall and by PD-L1 (clone 28-8 and 22C3) expression in tumor

		Clone 28-8 in tumor			Clone 22C3 in tumor
	Overall	≥1%	<1%	p-value	≥1%	<1%	p-value
	(n=191)	(n=49)	(n=142)		(n=22)	(n=169)
Age, years, median (range)	52 (25-86)	52 (31-74)	53 (25-86)	0.35	53 (33-72)	52 (25-86)	0.70
Nottingham grade, n (%)				0.01			0.32
1-2	55 (28.8)	7 (14.3)	48 (33.8)		4 (18.2)	51 (30.2)
3	136 (71.2)	42 (85.7)	94 (66.2)		18 (81.8)	118 (69.8)
Tumor Size, mm, median (range)	21 (1-80)	25 (8-80)	20 (1-70)	0.01	22 (8-45)	20 (1-80)	0.20
T-stage, n (%)				0.05			0.07
0	1 (0.5)	0 (0)	1 (0.7)		0 (0)	1 (0.6)
1	94 (49.2)	17 (34.7)	77 (54.2)		6 (27.3)	88 (52.1)
2	88 (46.1)	28 (57.1)	60 (42.3)		14 (63.6)	74 (43.8)
3	6 (3.1)	3 (6.1)	3 (2.1)		1 (4.5)	5 (3.0)
4	2 (1.1)	1 (2.0)	1 (0.7)		1 (4.5)	1 (0.6)
N-stage, n (%)				0.92			0.39
0	78 (40.8)	21 (42.9)	57 (40.1)		8 (36.4)	70 (41.4)
1	72 (37.7)	18 (36.7)	54 (38.0)		10 (45.5)	62 (36.7)
2	25 (13.1)	7 (14.3)	18 (12.7)		4 (18.2)	21 (12.4)
3	16 (8.4)	3 (2.0)	13 (9.2)		0 (0)	16 (9.5)
Hormonal receptor, n (%)				0.03			1.00
Positive	75 (39.3)	26 (53.1)	49 (34.5)		9 (40.9)	66 (39.1)
Negative	115 (60.2)	23 (46.9)	92 (64.8)		13 (59.1)	102 (60.4)
Hormonal Therapy, n(%)				0.06			1.00
No	72(37.7)	24(49.0)	48(33.8)		8(36.4)	64(37.9)
Yes	109(57.1)	22(44.9)	87(61.3)		12(54.5)	97(57.4)
Radiation Therapy, n(%)				0.85			0.294
No	47(24.6)	13(26.5)	34(23.9)		3(13.6)	44(26.0)
Yes	141(73.8)	35(71.4)	105(73.9)		19(86.4)	122(72.2)
Trastuzumab, n(%)				0.066			0.010
No	76(39.8)	14(28.6)	62(43.7)		3(13.6)	73(43.2)
Yes	115(60.2)	35(71.4)	80(56.3)		19(86.4)	96(56.8)
TIL-Str, %, median (range)	15 (0-85)	30 (0-85)	15 (0-65)	<0.001	40 (7.5-85)	15 (0-65)	<0.001